PL2949670T3 - Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie - Google Patents

Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie

Info

Publication number: PL2949670T3
Authority: PL; Poland
Prior art keywords: extracellular domain; antibodies binding; human csf1r; binding preferentially; preferentially human
Prior art date: 2009-12-10

Application number

PL15168902T

Other languages

English (en)

Inventor

Nikolaos Dimoudis

Klaus Kaluza

Stefan Seeber

Georg Fertig

Martin Lanzendoerfer

Carola Ries

Marlene Thomas

Alexander Fidler

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-10

Filing date

2010-12-07

Publication date

2019-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2949670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-12-07 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

2019-07-31 Publication of PL2949670T3 publication Critical patent/PL2949670T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL15168902T 2009-12-10 2010-12-07 Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie PL2949670T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP09015310		2009-12-10
EP10173407		2010-08-19
PCT/EP2010/069090 WO2011070024A1 (en)	2009-12-10	2010-12-07	Antibodies binding preferentially human csf1r extracellular domain 4 and their use
EP10794936.4A EP2510010B1 (en)	2009-12-10	2010-12-07	Antibodies binding to human CSF1R extracellular domain 4 and their use
EP15168902.3A EP2949670B1 (en)	2009-12-10	2010-12-07	Antibodies binding preferentially human csf1r extracellular domain 4 and their use

Publications (1)

Publication Number	Publication Date
PL2949670T3 true PL2949670T3 (pl)	2019-07-31

Family

ID=43735019

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15168902T PL2949670T3 (pl)	2009-12-10	2010-12-07	Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie
PL10794936T PL2510010T3 (pl)	2009-12-10	2010-12-07	Przeciwciała wiążące zewnątrzkomórkową domenę 4 ludzkiego CSF1R i ich zastosowanie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL10794936T PL2510010T3 (pl)	2009-12-10	2010-12-07	Przeciwciała wiążące zewnątrzkomórkową domenę 4 ludzkiego CSF1R i ich zastosowanie

Country Status (36)

Country	Link
US (10)	US8999327B2 (pl)
EP (2)	EP2949670B1 (pl)
JP (3)	JP5677451B2 (pl)
KR (1)	KR101434070B1 (pl)
CN (2)	CN102791738B (pl)
AR (1)	AR079333A1 (pl)
AU (2)	AU2010329934B2 (pl)
BR (1)	BR112012013717B1 (pl)
CA (1)	CA2780692C (pl)
CL (1)	CL2012001547A1 (pl)
CO (1)	CO6541621A2 (pl)
CR (1)	CR20120215A (pl)
CY (1)	CY1117331T1 (pl)
DK (2)	DK2510010T3 (pl)
EC (1)	ECSP12011964A (pl)
ES (2)	ES2722300T3 (pl)
HK (2)	HK1219739A1 (pl)
HR (2)	HRP20160131T1 (pl)
HU (2)	HUE044179T2 (pl)
IL (1)	IL219595A (pl)
LT (1)	LT2949670T (pl)
MA (1)	MA34780B1 (pl)
MX (2)	MX2012006553A (pl)
MY (1)	MY159679A (pl)
NZ (1)	NZ599516A (pl)
PE (1)	PE20121398A1 (pl)
PH (1)	PH12012500881A1 (pl)
PL (2)	PL2949670T3 (pl)
PT (2)	PT2510010E (pl)
RS (2)	RS58693B1 (pl)
RU (1)	RU2565541C2 (pl)
SG (1)	SG181589A1 (pl)
SI (2)	SI2949670T1 (pl)
TW (1)	TWI422388B (pl)
WO (1)	WO2011070024A1 (pl)
ZA (1)	ZA201203782B (pl)

Families Citing this family (246)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2949670T3 (pl)	2009-12-10	2019-07-31	F. Hoffmann-La Roche Ag	Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie
EP2542588A1 (en)	2010-03-05	2013-01-09	F. Hoffmann-La Roche AG	Antibodies against human csf-1r and uses thereof
WO2011107553A1 (en)	2010-03-05	2011-09-09	F. Hoffmann-La Roche Ag	Antibodies against human csf-1r and uses thereof
SG10201911345WA (en)	2010-05-04	2020-01-30	Five Prime Therapeutics Inc	Antibodies that bind csf1r
JP2014520873A (ja)	2011-07-18	2014-08-25	ザユニバーシティオブメルボルン	ｃ−Ｆｍｓアンタゴニストの使用
CN103958546B (zh) *	2011-10-21	2017-10-27	特朗斯吉有限公司	巨噬细胞活化的调节
MX356337B (es)	2011-12-15	2018-05-23	Hoffmann La Roche	Anticuerpos contra csf-1r humano y sus usos.
AR090263A1 (es) *	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en)	2012-05-11	2013-11-14	Five Prime Therapeutics, Inc.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
JP2015517490A (ja) *	2012-05-11	2015-06-22	ファイブプライムセラピューティックスインコーポレイテッド	コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
RU2718751C2 (ru)	2012-08-31	2020-04-14	Файв Прайм Терапьютикс, Инк.	Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
CN109793893B (zh)	2012-09-07	2023-05-26	达特茅斯大学理事会	用于诊断和治疗癌症的vista调节剂
US9676859B2 (en) *	2012-11-09	2017-06-13	Transgene Sa	In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody
SG11201507871XA (en)	2013-04-12	2015-10-29	Morphosys Ag	Antibodies targeting m-csf
AR095882A1 (es) *	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en)	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
DK3087098T3 (da) *	2013-12-24	2020-06-08	Janssen Pharmaceutica Nv	Anti-Vista-antistoffer og -fragmenter
US20160318928A1 (en)	2013-12-24	2016-11-03	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
US10987322B2 (en)	2014-06-06	2021-04-27	Flexus Biosciences, Inc.	Immunoregulatory agents
WO2015187835A2 (en)	2014-06-06	2015-12-10	Bristol-Myers Squibb Company	Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
BR112016029460A2 (pt)	2014-06-23	2017-10-24	Five Prime Therapeutics Inc	métodos para tratar artrite reumatoide
US9765147B2 (en)	2014-10-29	2017-09-19	Five Prime Therapeutics, Inc.	Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
AR102537A1 (es)	2014-11-05	2017-03-08	Flexus Biosciences Inc	Agentes inmunomoduladores
EA201790806A1 (ru)	2014-11-05	2017-11-30	Флексус Байосайенсиз, Инк.	Иммунорегулирующие средства
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
ME03806B (me)	2014-11-21	2021-04-20	Bristol Myers Squibb Co	Antitela protiv cd73 i njihova upotreba
TW201630907A (zh)	2014-12-22	2016-09-01	必治妥美雅史谷比公司	ＴＧＦβＲ拮抗劑
AU2015369854B2 (en)	2014-12-22	2021-07-01	Five Prime Therapeutics, Inc.	Anti-CSF1R antibodies for treating PVNS
MX2017007744A (es)	2014-12-23	2017-09-05	Bristol Myers Squibb Co	Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
US10983128B2 (en)	2015-02-05	2021-04-20	Bristol-Myers Squibb Company	CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
MY186133A (en)	2015-03-02	2021-06-24	Rigel Pharmaceuticals Inc	Tgf-? inhibitors
CA2981584A1 (en)	2015-04-03	2016-10-06	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
TW201642897A (zh)	2015-04-08	2016-12-16	Ｆ星生物科技有限公司	Ｈｅｒ２結合劑治療
HUE053903T2 (hu)	2015-04-13	2021-07-28	Five Prime Therapeutics Inc	Kombinációs terápia rák ellen
EP3294736B1 (en)	2015-05-11	2020-07-22	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
ES2770349T3 (es)	2015-05-12	2020-07-01	Bristol Myers Squibb Co	Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
US9725449B2 (en)	2015-05-12	2017-08-08	Bristol-Myers Squibb Company	Tricyclic compounds as anticancer agents
JP6688551B2 (ja)	2015-05-21	2020-04-28	ハープーンセラピューティクス，インク．	三重特異性結合タンパク質と使用方法
SI3303396T1 (sl)	2015-05-29	2023-01-31	Bristol-Myers Squibb Company	Protitelesa proti OX40 in njihova uporaba
EP3108897A1 (en)	2015-06-24	2016-12-28	F. Hoffmann-La Roche AG	Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP3313442B1 (en) *	2015-06-24	2019-10-16	H. Hoffnabb-La Roche Ag	Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
BR112017028353A2 (pt)	2015-06-29	2018-09-04	The Rockfeller University	anticorpos para cd40 com atividade agonista melhorada
EP3328861A1 (en)	2015-07-28	2018-06-06	Bristol-Myers Squibb Company	Tgf beta receptor antagonists
KR20180042370A (ko)	2015-08-25	2018-04-25	브리스톨-마이어스 스큅 컴퍼니	Tgf 베타 수용체 길항제
CA2998350A1 (en) *	2015-09-16	2017-03-23	John Lippincott	Anti-cd115 antibodies
ES2809125T3 (es)	2015-09-23	2021-03-03	Bristol Myers Squibb Co	Moléculas de armazón a base de fibronectina de unión a glipicano-3
KR20180082563A (ko)	2015-11-19	2018-07-18	브리스톨-마이어스 스큅 컴퍼니	글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
EP3390406A1 (en)	2015-12-15	2018-10-24	Bristol-Myers Squibb Company	Cxcr4 receptor antagonists
BR112018067368A2 (pt)	2016-03-04	2019-01-15	Bristol-Myers Squibb Company	terapia de combinação com anticorpos anti-cd73
CN117562992A (zh)	2016-04-15	2024-02-20	伊穆奈克斯特股份有限公司	抗人vista抗体及其用途
CN116059351A (zh)	2016-04-18	2023-05-05	塞德斯医疗公司	结合人cd40的激动性抗体及其用途
CN105820250B (zh) *	2016-04-29	2019-04-30	中国人民解放军第四军医大学	一种抗basigin人源化抗体及其应用
JP2019516687A (ja)	2016-05-04	2019-06-20	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
WO2017192811A1 (en)	2016-05-04	2017-11-09	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190003686A (ko)	2016-05-04	2019-01-09	브리스톨-마이어스 스큅 컴퍼니	인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2017192844A1 (en)	2016-05-04	2017-11-09	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2019516681A (ja)	2016-05-04	2019-06-20	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
JP6683020B2 (ja)	2016-06-01	2020-04-15	株式会社デンソー	電力変換装置、及び、これを用いた電動パワーステアリング装置
WO2017210335A1 (en)	2016-06-01	2017-12-07	Bristol-Myers Squibb Company	Imaging methods using 18f-radiolabeled biologics
EP3471754A1 (en)	2016-06-20	2019-04-24	Kymab Limited	Anti-pd-l1 antibodies
KR102493282B1 (ko)	2016-07-14	2023-02-01	브리스톨-마이어스 스큅 컴퍼니	Tim3에 대한 항체 및 그의 용도
WO2018017633A1 (en)	2016-07-21	2018-01-25	Bristol-Myers Squibb Company	TGF Beta RECEPTOR ANTAGONISTS
WO2018036852A1 (en)	2016-08-25	2018-03-01	F. Hoffmann-La Roche Ag	Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
US11351164B2 (en)	2016-08-26	2022-06-07	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2019528301A (ja)	2016-08-26	2019-10-10	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
JP2018047144A (ja) *	2016-09-23	2018-03-29	株式会社三共	スロットマシン
JP2018047145A (ja) *	2016-09-23	2018-03-29	株式会社三共	スロットマシン
JP2018047147A (ja) *	2016-09-23	2018-03-29	株式会社三共	スロットマシン
JP2018047146A (ja) *	2016-09-23	2018-03-29	株式会社三共	スロットマシン
JP2018061577A (ja) *	2016-10-11	2018-04-19	株式会社三共	スロットマシン
US10660909B2 (en)	2016-11-17	2020-05-26	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists
JP7304287B2 (ja)	2016-12-22	2023-07-06	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
US10961239B2 (en)	2017-01-05	2021-03-30	Bristol-Myers Squibb Company	TGF beta receptor antagonists
KR102611446B1 (ko)	2017-01-20	2023-12-06	아르커스 바이오사이언시즈 인코포레이티드	암-관련 장애의 치료를 위한 아졸로피리미딘
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
EP3612563A1 (en)	2017-04-19	2020-02-26	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
EP3612030A4 (en)	2017-04-21	2021-04-28	Ikena Oncology, Inc.	AHR INDOLE INHIBITORS AND THEIR USES
US11066392B2 (en)	2017-05-12	2021-07-20	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018209298A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
CN110636846B (zh)	2017-05-17	2023-05-16	艾库斯生物科学有限公司	用于治疗癌症相关疾病的喹唑啉吡唑衍生物
US12168054B2 (en)	2017-05-19	2024-12-17	Syndax Pharmaceuticals, Inc.	Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
JP2020526520A (ja)	2017-06-30	2020-08-31	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｉｄｏ阻害剤の非晶質形体および結晶形体
EP3658565B1 (en)	2017-07-28	2022-11-09	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
ES2926195T3 (es)	2017-08-04	2022-10-24	Bicycletx Ltd	Ligandos peptídicos bicíclicos específicos de CD137
US10696650B2 (en)	2017-08-17	2020-06-30	Ikena Oncology, Inc.	AHR inhibitors and uses thereof
CN111032672B (zh)	2017-08-31	2024-09-13	百时美施贵宝公司	作为抗癌剂的环二核苷酸
US10947263B2 (en)	2017-08-31	2021-03-16	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
US10953032B2 (en)	2017-08-31	2021-03-23	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
CN111479586A (zh)	2017-09-13	2020-07-31	戊瑞治疗有限公司	用于胰腺癌的组合抗csf1r和抗pd-1抗体的组合疗法
WO2019060693A1 (en)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	CRBN LIGANDS AND USES THEREOF
JP7366031B2 (ja)	2017-09-22	2023-10-20	カイメラセラピューティクス，インコーポレイテッド	タンパク質分解剤およびそれらの使用
US11649212B2 (en)	2017-10-09	2023-05-16	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en)	2017-10-09	2019-04-18	Bristol-Myers Squibb Company	INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
WO2019074887A1 (en)	2017-10-10	2019-04-18	Bristol-Myers Squibb Company	CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
JP7254821B2 (ja)	2017-10-16	2023-04-10	ブリストル－マイヤーズスクイブカンパニー	抗がん剤としての環状ジヌクレオチド
CN111542544A (zh)	2017-11-01	2020-08-14	百时美施贵宝公司	用于治疗癌症的免疫刺激性激动性抗体
WO2019090198A1 (en)	2017-11-06	2019-05-09	Bristol-Myers Squibb Company	Isofuranone compounds useful as hpk1 inhibitors
CN111406112A (zh)	2017-11-30	2020-07-10	豪夫迈·罗氏有限公司	用于培养哺乳动物细胞的工艺
EP3720881A1 (en)	2017-12-08	2020-10-14	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
JP7284759B2 (ja)	2017-12-27	2023-05-31	ブリストル－マイヤーズスクイブカンパニー	抗ｃｄ４０抗体およびその使用
WO2019136112A1 (en)	2018-01-05	2019-07-11	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140380A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
US12129297B2 (en)	2018-01-12	2024-10-29	Bristol-Myers Squibb Company	Antibodies against TIM3 and uses thereof
WO2019140387A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
CN108276495B (zh) *	2018-01-24	2022-03-18	博生吉医药科技(苏州)有限公司	靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
WO2019147982A1 (en)	2018-01-26	2019-08-01	Celldex Therapeutics, Inc.	Methods of treating cancer with dendritic cell mobilizing agents
IL312674A (en)	2018-01-29	2024-07-01	Merck Patent Gmbh	GCN2 inhibitors and uses thereof
IL301089A (en)	2018-01-29	2023-05-01	Vertex Pharma	Gcn2 inhibitors and uses thereof
US10519187B2 (en)	2018-02-13	2019-12-31	Bristol-Myers Squibb Company	Cyclic dinucleotides as anticancer agents
WO2019165315A1 (en)	2018-02-23	2019-08-29	Syntrix Biosystems Inc.	Method for treating cancer using chemokine antagonists alone or in combination
US11692029B2 (en)	2018-03-05	2023-07-04	The Schepens Eye Research Institute, Inc.	Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
CN111801341B (zh)	2018-03-08	2023-10-24	百时美施贵宝公司	作为抗癌剂的环二核苷酸
KR20200135421A (ko)	2018-03-21	2020-12-02	파이브 프라임 테라퓨틱스, 인크.	산성 pH에서 VISTA에 결합하는 항체
MX2020009861A (es)	2018-03-23	2020-10-08	Bristol Myers Squibb Co	Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CA3094112A1 (en)	2018-03-28	2019-10-03	Bristol-Myers Squibb Company	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2020010604A (es)	2018-04-12	2020-10-20	Bristol Myers Squibb Co	Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
CA3096546A1 (en)	2018-04-16	2019-10-24	Arrys Therapeutics, Inc.	Ep4 inhibitors and use thereof
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
CA3104647A1 (en)	2018-06-27	2020-01-02	Bristol-Myers Squibb Company	Naphthyridinone compounds useful as t cell activators
PL3814348T3 (pl)	2018-06-27	2023-09-11	Bristol-Myers Squibb Company	Podstawione związki naftyrydynonu przydatne jako aktywatory komórek t
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
EP3820904A2 (en)	2018-07-09	2021-05-19	Five Prime Therapeutics, Inc.	Antibodies binding to ilt4
BR112021000303A2 (pt)	2018-07-11	2021-04-13	Five Prime Therapeutics, Inc.	Anticorpos que se ligam a vista em ph ácido
WO2020018680A1 (en)	2018-07-18	2020-01-23	Arcus Biosciences, Inc.	Solid forms of an azolopyrimidine compound
CN109096397B (zh) *	2018-07-18	2019-04-16	博奥信生物技术（南京）有限公司	一种抗人csf-1r单克隆抗体及应用
US12059420B2 (en)	2018-07-23	2024-08-13	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12145927B2 (en)	2018-07-23	2024-11-19	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en)	2018-08-29	2021-03-30	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en)	2018-08-29	2022-02-22	Bristol-Myers Squibb Company	Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN113164419A (zh)	2018-09-07	2021-07-23	皮克医疗公司	Eif4e抑制剂和其用途
AU2019339740A1 (en)	2018-09-13	2021-04-01	F. Hoffmann-La Roche Ag	Csf-1r antibody formulation
WO2020061482A1 (en)	2018-09-21	2020-03-26	Harpoon Therapeutics, Inc.	Egfr binding proteins and methods of use
CN113286817B (zh)	2018-09-25	2025-01-28	哈普恩治疗公司	Dll3结合蛋白及使用方法
AU2019346645A1 (en)	2018-09-27	2021-04-29	Marengo Therapeutics, Inc.	CSF1R/CCR2 multispecific antibodies
TW202035445A (zh)	2018-10-10	2020-10-01	美商帝洛斯療法股份有限公司	抗lap抗體變異體及其用途
US11274150B2 (en)	2018-11-16	2022-03-15	Bristol-Myers Squibb Company	Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
US12226425B2 (en)	2018-11-16	2025-02-18	Arcus Biosciences, Inc.	Inhibitors of ARG1 and/or ARG2
EP3886904A4 (en)	2018-11-30	2022-07-13	Kymera Therapeutics, Inc.	IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES
WO2020123444A1 (en)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
SG11202109066RA (en)	2019-03-19	2021-09-29	Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron	Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
KR20210144821A (ko)	2019-03-29	2021-11-30	아르커스 바이오사이언시즈 인코포레이티드	규명된 아데노신 지문을 이용한 암의 치료방법
WO2020201753A1 (en)	2019-04-02	2020-10-08	Bicycletx Limited	Bicycle toxin conjugates and uses thereof
KR20220006139A (ko)	2019-04-05	2022-01-14	카이메라 쎄라퓨틱스 인코포레이티드	Stat 분해제 및 이의 용도
WO2020231713A1 (en)	2019-05-13	2020-11-19	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2020231766A1 (en)	2019-05-13	2020-11-19	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2020243423A1 (en)	2019-05-31	2020-12-03	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2021026179A1 (en)	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	AGONISTS OF ROR GAMMAt
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119821A1 (es)	2019-08-28	2022-01-12	Bristol Myers Squibb Co	Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CN114945366B (zh)	2019-09-13	2025-01-07	林伯士萨顿公司	Hpk1拮抗剂和其用途
CA3149719A1 (en)	2019-09-19	2021-03-25	Bristol-Myers Squibb Company	Antibodies binding to vista at acidic ph
EP4034558A1 (en)	2019-09-26	2022-08-03	Roche Diagnostics GmbH	Anti-csf-1r antibody
IL293027A (en)	2019-11-19	2022-07-01	Bristol Myers Squibb Co	Compounds useful as inhibitors of helios protein
IL293326A (en)	2019-11-26	2022-07-01	Ikena Oncology Inc	Polymorphic carbazole derivatives and uses thereof
IL293357A (en)	2019-11-26	2022-07-01	Bristol Myers Squibb Co	Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
JP2023509366A (ja)	2019-12-17	2023-03-08	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
US11591332B2 (en)	2019-12-17	2023-02-28	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
CA3162992A1 (en)	2019-12-23	2021-07-01	Louis S. Chupak	Substituted quinolinonyl piperazine compounds useful as t cell activators
CN115297931A (zh)	2019-12-23	2022-11-04	凯麦拉医疗公司	Smarca降解剂和其用途
US20230118629A1 (en)	2019-12-23	2023-04-20	Bristol-Myers Squibb Company	Substituted piperazine derivatives useful as t cell activators
CN114846015B (zh)	2019-12-23	2024-07-30	百时美施贵宝公司	用作t细胞激活剂的经取代的杂芳基化合物
CN114846007B (zh)	2019-12-23	2024-11-22	百时美施贵宝公司	可用作t细胞激活剂的经取代的喹唑啉基化合物
AR120823A1 (es)	2019-12-23	2022-03-23	Bristol Myers Squibb Co	Compuestos bicíclicos sustituidos útiles como activadores de células t
KR20220117320A (ko) *	2019-12-24	2022-08-23	아다젠 (수저우) 리미티드	항 csf1r 분자 및 이의 용도
IL294466A (en)	2020-01-07	2022-09-01	Hifibio Hk Ltd	Anti-galectin-9 antibody and uses thereof
BR112022017727A2 (pt)	2020-03-03	2022-11-16	Pic Therapeutics Inc	Inibidores de eif4e e usos dos mesmos
WO2021183428A1 (en)	2020-03-09	2021-09-16	Bristol-Myers Squibb Company	Antibodies to cd40 with enhanced agonist activity
KR20230005160A (ko)	2020-03-19	2023-01-09	카이메라 쎄라퓨틱스 인코포레이티드	Mdm2 분해제 및 이의 용도
JP7474861B2 (ja)	2020-03-19	2024-04-25	アーカスバイオサイエンシーズ，インコーポレーテッド	Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物
TW202140441A (zh)	2020-03-23	2021-11-01	美商必治妥美雅史谷比公司	經取代之側氧基異吲哚啉化合物
GB202005274D0 (en)	2020-04-09	2020-05-27	Univ Surrey	Monocyte
EP4132971A1 (en)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en)	2020-05-15	2021-11-18	Bristol-Myers Squibb Company	Antibodies to garp
AU2021284273A1 (en)	2020-06-02	2022-12-15	Arcus Biosciences, Inc.	Antibodies to TIGIT
US20230250110A1 (en)	2020-06-03	2023-08-10	Kymera Therapeutics, Inc.	Deuterated irak degraders and uses thereof
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
US11649261B2 (en)	2020-06-17	2023-05-16	Arcus Biosciences, Inc.	Crystalline forms of a CD73 inhibitor and uses thereof
EP4178611A1 (en)	2020-07-07	2023-05-17	BioNTech SE	Therapeutic rna for hpv-positive cancer
IL300175A (en)	2020-07-30	2023-03-01	Kymera Therapeutics Inc	Methods of treating mutant lymphomas
CA3186504A1 (en)	2020-08-17	2022-02-24	Stephen J. Blakemore	Bicycle conjugates specific for nectin-4 and uses thereof
KR20230131189A (ko)	2020-12-02	2023-09-12	이케나 온콜로지, 인코포레이티드	Tead 억제제 및 이의 용도
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
PH12023500015A1 (en)	2020-12-30	2024-03-11	Kymera Therapeutics Inc	Irak degraders and uses thereof
US20240325554A1 (en)	2021-01-11	2024-10-03	Bicycle TX Limited	Methods for treating cancer
CA3206499A1 (en)	2021-02-02	2022-08-11	Liminal Biosciences Limited	Gpr84 antagonists and uses thereof
BR112023015590A2 (pt)	2021-02-02	2023-10-17	Liminal Biosciences Ltd	Antagonistas de gpr84 e usos dos mesmos
WO2022169921A1 (en)	2021-02-04	2022-08-11	Bristol-Myers Squibb Company	Benzofuran compounds as sting agonists
EP4291235A4 (en)	2021-02-12	2025-01-08	Nimbus Saturn Inc	HPK1 ANTAGONISTS AND THEIR USES
CN116867494A (zh)	2021-02-15	2023-10-10	凯麦拉医疗公司	Irak4降解剂和其用途
US12171768B2 (en)	2021-02-15	2024-12-24	Kymera Therapeutics, Inc.	IRAK4 degraders and uses thereof
EP4301756A4 (en)	2021-03-05	2025-02-26	Nimbus Saturn Inc	HPK1 ANTAGONISTS AND THEIR USES
US11918582B2 (en)	2021-03-15	2024-03-05	Rapt Therapeutics, Inc.	Pyrazole pyrimidine compounds and uses thereof
WO2022213062A1 (en)	2021-03-29	2022-10-06	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
EP4314068A1 (en)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
EP4320125A1 (en)	2021-04-05	2024-02-14	Bristol-Myers Squibb Company	Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
WO2022216644A1 (en)	2021-04-06	2022-10-13	Bristol-Myers Squibb Company	Pyridinyl substituted oxoisoindoline compounds
CA3215081A1 (en)	2021-04-16	2022-10-20	Alfredo C. Castro	Mek inhibitors and uses thereof
CN117715904A (zh)	2021-05-07	2024-03-15	凯麦拉医疗公司	Cdk2降解剂和其用途
CN117337288A (zh)	2021-05-21	2024-01-02	艾库斯生物科学有限公司	Axl抑制剂化合物
US20240246967A1 (en)	2021-05-21	2024-07-25	Arcus Biosciences, Inc.	Axl compounds
MX2024000674A (es)	2021-07-13	2024-02-07	BioNTech SE	Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
AU2022327766A1 (en)	2021-08-13	2023-12-14	Ludwig-Maximilians-Universität München	Anti-csf1r car expressing lymphocytes for targeted tumor therapy
EP4392422A1 (en)	2021-08-25	2024-07-03	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
JP2024532276A (ja)	2021-08-25	2024-09-05	ピクセラピューティクス，インコーポレイテッド	ｅＩＦ４Ｅ阻害剤及びその使用
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
TW202334165A (zh)	2021-10-29	2023-09-01	美商凱麥拉醫療公司	Irak4降解劑及其製備
KR20240110814A (ko)	2021-10-29	2024-07-16	아르커스 바이오사이언시즈 인코포레이티드	Hif-2알파의 저해제 및 이의 사용 방법
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
JP2025504059A (ja)	2022-01-31	2025-02-06	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋデグレーダー及びその使用
CN118946556A (zh)	2022-02-01	2024-11-12	阿维纳斯运营公司	Dgk靶向化合物及其用途
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
EP4518895A1 (en)	2022-05-02	2025-03-12	Arcus Biosciences, Inc.	Anti-tigit antibodies and uses of the same
IL316768A (en)	2022-05-25	2025-01-01	Ikena Oncology Inc	MEK inhibitors and their uses
US20240124490A1 (en)	2022-07-15	2024-04-18	Arcus Biosciences, Inc.	Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en)	2022-07-20	2024-01-25	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
WO2024028364A1 (en)	2022-08-02	2024-02-08	Liminal Biosciences Limited	Aryl-triazolyl and related gpr84 antagonists and uses thereof
AU2023317740A1 (en)	2022-08-02	2025-03-13	Liminal Biosciences Limited	Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
TW202416972A (zh)	2022-08-02	2024-05-01	英商利米那生物科技有限公司	經取代之吡啶酮gpr84拮抗劑及其用途
CN119654312A (zh)	2022-08-08	2025-03-18	百时美施贵宝公司	用作t细胞活化剂的取代的四唑基化合物
CN119677740A (zh)	2022-08-09	2025-03-21	百时美施贵宝公司	用作t细胞活化剂的叔胺取代的双环化合物
WO2024081385A1 (en)	2022-10-14	2024-04-18	Arcus Biosciences, Inc.	Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en)	2022-10-20	2024-04-25	Arcus Biosciences, Inc.	Lyophilized formulations of cd73 compounds
WO2024112894A1 (en)	2022-11-22	2024-05-30	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
WO2024126457A1 (en)	2022-12-14	2024-06-20	Astellas Pharma Europe Bv	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024156672A1 (en)	2023-01-25	2024-08-02	F. Hoffmann-La Roche Ag	Antibodies binding to csf1r and cd3
US20240425497A1 (en)	2023-05-05	2024-12-26	Arcus Biosciences, Inc.	Cbl-b Inhibitors and Methods of Use Thereof
KR20250019700A (ko)	2023-05-08	2025-02-10	브리스톨-마이어스 스큅 컴퍼니	치환된 페닐 옥사졸론 화합물
WO2024238787A1 (en)	2023-05-17	2024-11-21	Syndax Pharmaceuticals, Inc.	Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2024243502A1 (en)	2023-05-25	2024-11-28	Arcus Biosciences, Inc.	Cbl-b inhibitors and methods of use thereof
WO2024249540A1 (en)	2023-05-31	2024-12-05	Bristol-Myers Squibb Company	Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en)	2023-06-07	2024-12-12	Bristol-Myers Squibb Company	Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2025030002A2 (en)	2023-08-02	2025-02-06	Arvinas Operations, Inc.	Dgk targeting compounds and uses thereof
WO2025049840A1 (en)	2023-09-02	2025-03-06	Bristol-Myers Squibb Company	Substituted phenyl oxooxazolyl piperidine dione compounds
US20250084056A1 (en)	2023-09-13	2025-03-13	Bristol-Myers Squibb Company	Substituted oxoisoindolinyl piperidine-2,6-dione compounds

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5606040A (en) *	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) *	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) *	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0955365A3 (en)	1992-06-09	2000-12-20	Chiron Corporation	Crystallization of M-CSF
DE69303494T2 (de)	1992-11-13	1997-01-16	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635483A (en) *	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) *	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
UA40577C2 (uk)	1993-08-02	2001-08-15	Мерк Патент Гмбх	Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) *	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) *	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
JPH0967400A (ja)	1995-08-31	1997-03-11	Toray Ind Inc	モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
IL130864A0 (en)	1997-03-03	2001-01-28	Bristol Myers Squibb Co	Monoclonal antibodies to human cd6
ATE319745T1 (de)	1997-05-21	2006-03-15	Biovation Ltd	Verfahren zur herstellung von nicht-immunogenen proteinen
JP4891477B2 (ja)	1997-10-02	2012-03-07	マックス−プランク−ゲゼルシャフトツールフォーデルングデルヴィッセンシャフテンエー．ヴェー．	血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
WO2001030381A2 (de)	1999-10-28	2001-05-03	Hofbauer, Reinhold	Verwendung von csf-1-inhibitoren
ES2274823T3 (es) *	1999-12-29	2007-06-01	Immunogen, Inc.	Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
US7108852B2 (en)	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
DK1572106T3 (da)	2002-11-15	2010-08-23	Novartis Vaccines & Diagnostic	Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase
GB0325836D0 (en)	2003-11-05	2003-12-10	Celltech R&D Ltd	Biological products
PT2489364E (pt) *	2003-11-06	2015-04-16	Seattle Genetics Inc	Compostos de monometilvalina conjugados com anticorpos
EP1778842B8 (en)	2004-07-22	2012-03-21	Five Prime Therapeutics, Inc.	Compositions and methods of use for mgd-csf in disease treatment
AR054428A1 (es)	2005-03-08	2007-06-27	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina
US20090304687A1 (en)	2005-12-09	2009-12-10	Seattle Genetics , Inc.	Methods of using cd40 binding agents
JP5580535B2 (ja)	2006-01-05	2014-08-27	ノバルティスアーゲー	癌転移および癌転移に関連する骨量減少を予防および処置するための方法
US20070280935A1 (en)	2006-04-07	2007-12-06	Bernd Bohrmann	Antibody that recognizes phosphorylated peptides
AU2007333146A1 (en)	2006-12-12	2008-06-19	Idera Pharmaceuticals, Inc.	Synthetic agonists of TLR9
JP2010526767A (ja)	2007-03-30	2010-08-05	エフ．ホフマン−ラロシュアーゲー	標識された又は未標識のモノクローナル抗体の組成物
EP2155238B1 (en)	2007-06-05	2016-04-06	Yale University	Antibody against d4 domain of the kit receptor and use thereor
PL2188313T3 (pl) *	2007-08-21	2018-04-30	Amgen, Inc.	Białka wiążące ludzki antygen c-fms
US8470977B2 (en)	2008-03-14	2013-06-25	Transgene S.A.	Antibody against the CSF-1R
HUE028756T2 (en) *	2008-03-14	2017-01-30	Transgene Sa	Anti-CSF-1R antibody
US8709715B2 (en)	2008-03-26	2014-04-29	Cellerant Therapeutics, Inc.	Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
EP4331604B1 (en)	2008-12-09	2025-03-05	F. Hoffmann-La Roche AG	Anti-pd-l1 antibodies and their use to enhance t-cell function
PT2423228E (pt)	2009-04-20	2016-02-26	Kyowa Hakko Kirin Co Ltd	Anticorpo contendo igg2 em que foram introduzidas mutações de aminoácidos
SI3279215T1 (sl)	2009-11-24	2020-07-31	Medimmune Limited	Usmerjena vezavna sredstva proti B7-H1
PL2949670T3 (pl)	2009-12-10	2019-07-31	F. Hoffmann-La Roche Ag	Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie
WO2011107553A1 (en)	2010-03-05	2011-09-09	F. Hoffmann-La Roche Ag	Antibodies against human csf-1r and uses thereof
EP2542588A1 (en)	2010-03-05	2013-01-09	F. Hoffmann-La Roche AG	Antibodies against human csf-1r and uses thereof
TWI426920B (zh)	2010-03-26	2014-02-21	Hoffmann La Roche	雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
AR080698A1 (es)	2010-04-01	2012-05-02	Imclone Llc	Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
SG10201911345WA (en) *	2010-05-04	2020-01-30	Five Prime Therapeutics Inc	Antibodies that bind csf1r
JP5798404B2 (ja)	2010-08-31	2015-10-21	日東電工株式会社	極板保護用粘着テープ
JP2014520873A (ja)	2011-07-18	2014-08-25	ザユニバーシティオブメルボルン	ｃ−Ｆｍｓアンタゴニストの使用
CN103958546B (zh)	2011-10-21	2017-10-27	特朗斯吉有限公司	巨噬细胞活化的调节
MX356337B (es)	2011-12-15	2018-05-23	Hoffmann La Roche	Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es)	2012-02-06	2014-10-14	Genentech Inc	Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015517490A (ja)	2012-05-11	2015-06-22	ファイブプライムセラピューティックスインコーポレイテッド	コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
US20130302322A1 (en)	2012-05-11	2013-11-14	Five Prime Therapeutics, Inc.	Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104508173B (zh)	2012-07-24	2016-09-21	日立金属株式会社	靶材及其制造方法
RU2718751C2 (ru)	2012-08-31	2020-04-14	Файв Прайм Терапьютикс, Инк.	Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
US9676859B2 (en)	2012-11-09	2017-06-13	Transgene Sa	In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

2010
- 2010-12-07 PL PL15168902T patent/PL2949670T3/pl unknown
- 2010-12-07 HU HUE15168902 patent/HUE044179T2/hu unknown
- 2010-12-07 TW TW099142677A patent/TWI422388B/zh active
- 2010-12-07 DK DK10794936.4T patent/DK2510010T3/en active
- 2010-12-07 PL PL10794936T patent/PL2510010T3/pl unknown
- 2010-12-07 ES ES15168902T patent/ES2722300T3/es active Active
- 2010-12-07 DK DK15168902.3T patent/DK2949670T3/da active
- 2010-12-07 PT PT107949364T patent/PT2510010E/pt unknown
- 2010-12-07 EP EP15168902.3A patent/EP2949670B1/en active Active
- 2010-12-07 MA MA34923A patent/MA34780B1/fr unknown
- 2010-12-07 AU AU2010329934A patent/AU2010329934B2/en active Active
- 2010-12-07 PT PT15168902T patent/PT2949670T/pt unknown
- 2010-12-07 CN CN201080063488.2A patent/CN102791738B/zh active Active
- 2010-12-07 MX MX2012006553A patent/MX2012006553A/es active IP Right Grant
- 2010-12-07 WO PCT/EP2010/069090 patent/WO2011070024A1/en active Application Filing
- 2010-12-07 SG SG2012042313A patent/SG181589A1/en unknown
- 2010-12-07 JP JP2012542522A patent/JP5677451B2/ja active Active
- 2010-12-07 KR KR1020127017818A patent/KR101434070B1/ko active Active
- 2010-12-07 ES ES10794936.4T patent/ES2557454T3/es active Active
- 2010-12-07 RS RS20190530A patent/RS58693B1/sr unknown
- 2010-12-07 MY MYPI2012002592A patent/MY159679A/en unknown
- 2010-12-07 HU HUE10794936A patent/HUE026201T2/en unknown
- 2010-12-07 CA CA2780692A patent/CA2780692C/en active Active
- 2010-12-07 PH PH1/2012/500881A patent/PH12012500881A1/en unknown
- 2010-12-07 PE PE2012000793A patent/PE20121398A1/es active IP Right Grant
- 2010-12-07 RU RU2012128651/10A patent/RU2565541C2/ru active
- 2010-12-07 US US12/962,445 patent/US8999327B2/en active Active
- 2010-12-07 SI SI201031886T patent/SI2949670T1/sl unknown
- 2010-12-07 EP EP10794936.4A patent/EP2510010B1/en active Active
- 2010-12-07 CN CN201510673059.1A patent/CN105218672A/zh active Pending
- 2010-12-07 SI SI201031097T patent/SI2510010T1/sl unknown
- 2010-12-07 NZ NZ599516A patent/NZ599516A/xx unknown
- 2010-12-07 RS RS20160074A patent/RS54596B1/en unknown
- 2010-12-07 BR BR112012013717A patent/BR112012013717B1/pt active IP Right Grant
- 2010-12-07 LT LTEP15168902.3T patent/LT2949670T/lt unknown
- 2010-12-09 AR ARP100104542A patent/AR079333A1/es active IP Right Grant
2012
- 2012-04-26 CR CR20120215A patent/CR20120215A/es unknown
- 2012-05-03 IL IL219595A patent/IL219595A/en active IP Right Grant
- 2012-05-23 ZA ZA2012/03782A patent/ZA201203782B/en unknown
- 2012-05-30 CO CO12090413A patent/CO6541621A2/es unknown
- 2012-06-07 MX MX2014008680A patent/MX353706B/es unknown
- 2012-06-08 CL CL2012001547A patent/CL2012001547A1/es unknown
- 2012-06-08 EC ECSP12011964 patent/ECSP12011964A/es unknown
2013
- 2013-03-25 HK HK16107619.8A patent/HK1219739A1/zh unknown
- 2013-03-25 HK HK13103659.1A patent/HK1176361A1/zh unknown
2014
- 2014-10-29 US US14/527,097 patent/US9499624B2/en active Active
- 2014-12-25 JP JP2014262097A patent/JP2015120697A/ja active Pending
2015
- 2015-03-06 US US14/640,183 patent/US9499625B2/en active Active
- 2015-03-06 US US14/640,202 patent/US9499626B2/en active Active
- 2015-08-12 AU AU2015213308A patent/AU2015213308B2/en active Active
2016
- 2016-02-04 HR HRP20160131TT patent/HRP20160131T1/hr unknown
- 2016-02-18 CY CY20161100138T patent/CY1117331T1/el unknown
- 2016-10-13 US US15/292,710 patent/US9663580B2/en active Active
2017
- 2017-02-08 JP JP2017021279A patent/JP2017123850A/ja active Pending
- 2017-04-17 US US15/489,519 patent/US9879085B2/en active Active
- 2017-12-21 US US15/849,743 patent/US10072087B2/en active Active
2018
- 2018-01-19 US US15/875,530 patent/US10077314B1/en active Active
- 2018-08-06 US US16/055,947 patent/US10287358B2/en active Active
2019
- 2019-03-25 US US16/362,962 patent/US20190300614A1/en not_active Abandoned
- 2019-04-24 HR HRP20190762TT patent/HRP20190762T1/hr unknown

Also Published As

Publication number	Publication date
IL219595A0 (en)	2012-06-28
EP2510010A1 (en)	2012-10-17
AR079333A1 (es)	2012-01-18
CA2780692C (en)	2018-09-11
JP5677451B2 (ja)	2015-02-25
BR112012013717A2 (pt)	2017-01-10
EP2510010B1 (en)	2015-11-25
PT2949670T (pt)	2019-05-20
MY159679A (en)	2017-01-13
PL2510010T3 (pl)	2016-05-31
US20150274830A1 (en)	2015-10-01
PH12012500881A1 (en)	2017-07-26
US9499624B2 (en)	2016-11-22
HRP20160131T1 (hr)	2016-03-11
HUE026201T2 (en)	2016-05-30
CN102791738B (zh)	2015-10-07
CN102791738A (zh)	2012-11-21
BR112012013717B1 (pt)	2020-01-28
US8999327B2 (en)	2015-04-07
US9499626B2 (en)	2016-11-22
LT2949670T (lt)	2019-05-27
JP2017123850A (ja)	2017-07-20
CY1117331T1 (el)	2017-04-26
RU2565541C2 (ru)	2015-10-20
DK2949670T3 (da)	2019-05-13
CL2012001547A1 (es)	2012-10-12
AU2010329934B2 (en)	2015-05-14
TW201129381A (en)	2011-09-01
US20190071507A1 (en)	2019-03-07
ECSP12011964A (es)	2012-07-31
EP2949670A1 (en)	2015-12-02
EP2949670B1 (en)	2019-02-27
CR20120215A (es)	2012-06-01
JP2015120697A (ja)	2015-07-02
PE20121398A1 (es)	2012-10-26
NZ599516A (en)	2013-11-29
AU2010329934A1 (en)	2012-05-17
US9663580B2 (en)	2017-05-30
MX2012006553A (es)	2012-08-03
PT2510010E (pt)	2016-01-11
US20150158950A1 (en)	2015-06-11
IL219595A (en)	2017-03-30
DK2510010T3 (en)	2015-12-14
US20190300614A1 (en)	2019-10-03
HK1219739A1 (zh)	2017-04-13
CA2780692A1 (en)	2011-06-16
RS54596B1 (en)	2016-08-31
SI2510010T1 (sl)	2016-02-29
HUE044179T2 (hu)	2019-10-28
US20110165156A1 (en)	2011-07-07
JP2013513367A (ja)	2013-04-22
MX353706B (es)	2018-01-24
ES2722300T3 (es)	2019-08-09
ZA201203782B (en)	2017-01-25
US10077314B1 (en)	2018-09-18
KR101434070B1 (ko)	2014-08-25
RS58693B1 (sr)	2019-06-28
WO2011070024A1 (en)	2011-06-16
CN105218672A (zh)	2016-01-06
SI2949670T1 (sl)	2019-05-31
AU2015213308A1 (en)	2015-09-03
MA34780B1 (fr)	2014-01-02
US10287358B2 (en)	2019-05-14
US9499625B2 (en)	2016-11-22
HRP20190762T1 (hr)	2019-06-28
CO6541621A2 (es)	2012-10-16
AU2015213308B2 (en)	2017-09-14
RU2012128651A (ru)	2014-01-20
US20180208662A1 (en)	2018-07-26
HK1176361A1 (zh)	2013-07-26
TWI422388B (zh)	2014-01-11
US20180244788A1 (en)	2018-08-30
US10072087B2 (en)	2018-09-11
ES2557454T3 (es)	2016-01-26
SG181589A1 (en)	2012-07-30
US20170029517A1 (en)	2017-02-02
KR20120098872A (ko)	2012-09-05
US20150274831A1 (en)	2015-10-01
US20170320953A1 (en)	2017-11-09
US9879085B2 (en)	2018-01-30
BR112012013717A8 (pt)	2017-12-26

Publication	Publication Date	Title
HK1176361A1 (zh)	2013-07-26	優先結合人胞外域的抗體及其用途
ZA201307297B (en)	2019-07-31	Antibodies against human angiopoietin 2
ZA201103723B (en)	2012-09-26	Human antibodies against human tissue factor
ZA201102004B (en)	2011-12-28	Antibodies against human il 17 and uses thereof
HRP20181973T1 (hr)	2019-01-25	Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
PL2949666T3 (pl)	2019-07-31	Ludzkie przeciwciała przeciwko alfa-synukleinie
HK1151218A1 (en)	2012-01-27	Notch-binding agents and antagonists and methods of use thereof notch-
EP2512501A4 (en)	2014-01-01	METHODS FOR PROMOTING HAIR GROWTH USING FGFR3 EXTRACELLULAR DOMAINS
IL214355A0 (en)	2011-09-27	Antibodies against human tweak and uses thereof
EP2350112A4 (en)	2013-01-16	Site specific N-termin protein modifications and conjugate formation
GB0908868D0 (en)	2009-07-01	Depsipeptide and their therapeutic use
TH1201002740B (th)	2015-08-03	โดเมน 4 ภายนอกเซลล์ csf1r ของมนุษย์ที่ชอบการยึดเกาะแอนตี้บอดี้ และการใช้ของสิ่งเหล่านี้
HRP20190159T1 (hr)	2019-03-22	Antitijela humanog anti-alfa-sinukleina
GB0709038D0 (en)	2007-06-20	Novel receptor antagonists and their methods of use
GB0705802D0 (en)	2007-05-02	Novel receptor antagonists and their methods of use
GB0711439D0 (en)	2007-07-25	Novel receptor antagonists and their methods of use
SG10202006468XA (en)	2020-08-28	Human antibodies against human tissue factor
GB0814481D0 (en)	2008-09-10	Lactams and their tehrapeutic use